Journals / Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi / 2015 / Cilt: 12 - Sayı: 6

Intrahepatic Cholestasis Of Pregnancy And Its Management

Gebeliğin İntrahepatik Kolestazı ve Yönetimi

Pages
217–220
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the future, it’s expected that partially or complete alleviation of the disease may be provided at the hands of decryption and treatment of situations which cause genetic proneness, while it’s considered as a highly repetitive disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intrahepatic cholestasis of pregnancy ICP is the most frequent liver disease in pregnancy and is specific to pregnancy period.
📊
Key Findings & Data:Progressive increase in serum transaminase and bile acid levels are frequent laboratorial findings.
💡
Conclusion & Impact:In the future, it’s expected that partially or complete alleviation of the disease may be provided at the hands of decryption and treatment of situations which cause genetic proneness, while it’s considered as a highly repetitive disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Gebelik kolestazı · patogenez · yönetim

Abstract

Intrahepatic cholestasis of pregnancy ICP is the most frequent liver disease in pregnancy and is specific to pregnancy period. Genetic, hormonal, environmental factors have been accused in its pathogenesis. Pruritus is the first and the most frequent symptom of the disease. Progressive increase in serum transaminase and bile acid levels are frequent laboratorial findings. The maternal complications of ICP are rare, but include gallstones, cholecystitis, pancreatitis and liver cirrhosis. ICP also increases the risk of fetal and neonatal complications, such as perinatal mortality, stillbirth, low birth weight, fetal distress in labor and meconium aspiration, preterm labor and birth, fetal and neonatal arrhythmia. ICP may recur in subsequent pregnancies for more than 50 per cent. Ursodeoxycholic acid is the most effective therapeutic option to provide the best symptomatic and laboratorial results, but there’s not enough data to assure satisfying neonatal outcomes. Generally, induction of labor in the 37th weeks of gestation was showed to lower perinatal mortality in many studies. Studies to find out the genetic basis of the disease comprehensively are still carried on. In the future, it’s expected that partially or complete alleviation of the disease may be provided at the hands of decryption and treatment of situations which cause genetic proneness, while it’s considered as a highly repetitive disease.

Özet

Gebeliğin intrahepatik kolestazı, gebeliğe özgü olup, gebelikte en sık rastlanan karaciğer hastalığıdır. Patogenezinde genetik, hormonsal ve çevresel faktörler suçlanmıştır. Kaşıntı, ilk ve en sık gözlenen şikayettir. Karaciğer fonksiyonlarını gösteren serum transaminaz ve safra asitleri düzeylerinin ilerleyici artışı sık görülen laboratuvar bulgularıdır. Hastalığın maternal komplikasyonları safra taşları, kolesistit, pankreatit ve siroz gibi hastalıklar olup, nadir gelişir. Fetal ve neonatal açıdan da prematürite, düşük doğum ağırlığı, perinatal ölüm, mekonyum aspirasyon sendromu, eylemde fetal distres, fetal ve neonatal aritmi görülebilmektedir. Sonraki gebeliklerde %50 üzeri bir oranda tekrarlama olasılığı vadır. Tedavide en etkili semptomatik ve laboratuvar iyileşmesini sağlayan ilaç ursodeoksikolik asit olup, neonatal sonuçları iyileştirdiğine dair yeterli kanıt yoktur. Genelde, 37 gebelik haftasında indüklenen doğumun perinatal ölümü azalttığına dair çok sayıda veri vardır. Hastalığın genetik temellerine dair çalışmalar halen sürmektedir. Hastalığın büyük ölçüde tekrarlayıcı olabildiği düşünüldüğünde, gelecekte, genetik yatkınlık yaratan durumların tespit ve tedavisiyle, , daha hafif geçirilmesi veya tam iyileşme sağlanabilmesi beklenmektedir.

🔖

Cite This Article

UYGUR, D., ERSOY, A. Ö. (2022). Intrahepatic Cholestasis Of Pregnancy And Its Management. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, Cilt: 12 - Sayı: 6, 217–220. https://ajindex.com/articles/558846

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Heinonen S, Kirkinen P. Pregnancy outcome with intrahepatic cholesta- sis. Obstet Gynecol 1999;94:189-93.
  2. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of preg- nancy: Relationships between bile acid levels and fetal complication ra- tes. Hepatology 2004;40:467-74.
  3. Reyes H, Radrigan ME, Gonzalez MC, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology 1987;93:584- 90. Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. Journal of Hepatology 2006;44:1150–7
  4. Huang L, Zhao A, Lew JL, et al. Farnesoid X Receptor activates transcrip- tion of the phospholipid pump MDR3. J Biol Chem 2003;278:51085-90.
  5. Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E. Obstetric cholestasis with elevated gamma glutamyl transpeptida- se: Incidence, presentation and treatment. J Gastroenterol Hepatol 2003;18:1283. Lammert F, Marschall HU, Glantz A, Matern S. “Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management”. J Hepatol 2000;33: 1012–21.
  6. Meng LJ, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta J, Sjovall J. Progesterone metabolites and bile acids in serum of patients with int- rahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid the- rapy. Hepatology 1997;26:1573-1579. Reyes H. Review: Intrahepatic cholestasis. A puzzling disorder of preg- nancy. Journal of Gastroenterology and Hepatology 1997;12:211-216
  7. Kauppila A, Korpela H, Makila UM, et al. Low serum selenium concent- ration and glutathione peroxidase activity in intrahepatic cholestasis of pregnancy. Br Med J Clin Res Ed 1987;294:150-2.
  8. Agostini A, Gerli GC, Beretta L, et al. Erythrocyte antioxidant enzymes and selenium serumn levels in an Andean population. Clin Chim Acta 1983;133:153-7.
  9. Williamson C, Hems L, Goulis D, et al. Clinical outcome in a series of ca- ses of obstetric cholestasis identified via a patient support group. BJOG 2004;111:676-81
  10. Alsulyman OM, Ouzounian JG, Ames-Castro M, et al. Intrahepatic cho- lestasis of pregnancy: Perinatal outcome associated with expectant ma- nagement. Am J Obstet Gynecol 1996;175:957-60.
  11. Germain AM, Kato S, Carvajal JA, Valenzuela GJ, Valdes GL, Glasinovic JC. Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol 2003; 18:577-582.
  12. Sheikh Abdul Kadir SH, M